Cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab: Prophylaxis vs. pre-emptive strategies for prevention

Leukemia and Lymphoma

Volumn 47, Issue 12, 2006, Pages 2435-2436

  Worth, Leon J ^a,b   Thursky, Karin A ^a,b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; CYTOMEGALOVIRUS ANTIGEN PP65; GANCICLOVIR; VALACICLOVIR; VALGANCICLOVIR;

ALLOGENEIC STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG COST; HUMAN; IMMUNE DEFICIENCY; IMMUNOASSAY; INFECTION RISK; LEUKOPENIA; MYCOSIS; NEPHROTOXICITY; NOTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; VIRUS LOAD; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; SENSITIVITY AND SPECIFICITY; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33845596055     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190601090436     Document Type: Note

References (9)

1. Visani, G and (2006) An observational study of once weekly intravenous ganciclovir as CMV prophylaxis in heavily pre-treated chronic lymphocytic leukemia patients receiving subcutaneous alemtuzumab Leuk Lymphoma, 47, pp. 2542-2546.
2. Ng, A and (2005) Cytomegalovirus DNAemia and disease: Incidence, natural history and management in settings other than allogeneic stem cell transplantation Haematologica, 90, pp. 1672-1679.
3. O'Brien, S and Keating, M and Mocarski, E. (2006) Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab Clin Lymphoma Myeloma, 7, pp. 125-130.
4. Thursky, K and (2006) Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab Br J Haematol, 132, pp. 3-12.
5. O'Brien, S and (2005) A randomized trial of valacyclovir vs. valganciclovir to prevent CMV reactivation in patients with CLL receiving alemtuzumab Blood (ASH Annual Meeting Abstracts), 106, pp. 830A.
6. Laurenti, L and (2004) Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: Incidence and treatment with oral ganciclovir Haematologica, 89, pp. 1248-1252.
7. Gonzalez, H and Vernant, J and Caumes, E. (2005) Successful oral valganciclovir treatment of cytomegalovirus infection during Campath-1H therapy Leukemia, 19, pp. 478.
8. Keating, M and (2004) Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia Clin Lymphoma, 4, pp. 220-227.
9. Thursky, K and Byrnes, G and Grigg, A and Szer, J and Slavin, M. (2004) Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation Bone Marrow Transplant, 34, pp. 115-121.